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ABSTRACT Tuberculosis (TB) drug, regimen, and vaccine development rely heav-
ily on preclinical animal experiments, and quantification of bacterial and immune
response dynamics is essential for understanding drug and vaccine efficacy. A
mechanism-based model was built to describe Mycobacterium tuberculosis H37Rv in-
fection over time in BALB/c and athymic nude mice, which consisted of bacterial
replication, bacterial death, and adaptive immune effects. The adaptive immune ef-
fect was best described by a sigmoidal function on both bacterial load and incuba-
tion time. Applications to demonstrate the utility of this baseline model showed (i)
the important influence of the adaptive immune response on pyrazinamide (PZA)
drug efficacy, (ii) a persistent adaptive immune effect in mice relapsing after chemo-
therapy cessation, and (iii) the protective effect of vaccines after M. tuberculosis chal-
lenge. These findings demonstrate the utility of our model for describing M. tubercu-
losis infection and corresponding adaptive immune dynamics for evaluating the
efficacy of TB drugs, regimens, and vaccines.
KEYWORDS Mycobacterium tuberculosis, TB disease, mouse model, mechanistic
modeling, adaptive immunity, drug discovery and development, vaccine,
pyrazinamide
Tuberculosis (TB) caused by Mycobacterium tuberculosis infection has existed forthousands of years, and it is currently one of the top ten causes of death worldwide.
In 2017, an estimated 1.3 million HIV-negative people and 0.3 million HIV-positive
people died from TB, 10.0 million people fell ill with TB, and more than half a million
had multidrug-resistant TB (MDR-TB) (1). After several decades of inactivity, substantial
efforts have been made in the last 2 decades to develop new TB drugs, regimens, and
vaccines capable of ending the TB pandemic (2, 3).
Infection with M. tuberculosis starts with inhalation of airborne droplet nuclei
containing viable bacilli. The infected phagocytic cells in the lung, mainly macrophages,
will recruit additional macrophages and other immune cells, such as neutrophils,
monocytes, and dendritic cells (DCs), from neighboring blood vessels. As these cells are
recruited, they become infected by the expanding population of mycobacteria and
establish early granulomas, which are a pathological hallmark of TB (4–6). The immune
response toM. tuberculosis develops slowly. The early innate immune response has little
immediate antimycobacterial effect (5, 6). As a result, bacterial spread and replication
are still uninterrupted during this stage (5, 6). The increasing bacterial population
expands the infection range to include DCs, which subsequently migrate to the
draining lymph nodes of the lung. The antigens presented by DCs then activate the
naive antigen-specific T cells, initiating an adaptive immune response. The adaptive
immune response suppresses the replication of bacteria (6).
Effective adaptive cell-mediated immune responses to M. tuberculosis are critical
to controlling TB, as demonstrated by the adverse impacts of primary and acquired
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cell-mediated immune deficiency and the beneficial effects of priming and boosting
cell-mediated immune responses by Mycobacterium bovis bacillus Calmette-Guérin
(BCG) vaccination (7). Adaptive immune responses also improve the efficacy of che-
motherapy for TB. Combination chemotherapy results in lower rates of bacterial
elimination and higher relapse rates in athymic nude mice compared to those in
immunocompetent BALB/c mice (8–10). The antibacterial effect of the first-line drug
pyrazinamide (PZA) may be particularly dependent on cell-mediated immune re-
sponses, as it is strongly correlated with the local pH and probably exerts its maximal
sterilizing effects in the acidified microenvironment of phagosomes, where the pH can
be as low as 4.5 after macrophage activation by antigen-specific helper T cells (11, 12).
Therefore, the role of the adaptive immune response to M. tuberculosis must be
accounted for in the development of novel preventive and therapeutic strategies for TB
disease.
Animal models of TB are widely used for developing TB drugs, vaccines, and
diagnostic reagents, and for research on TB pathogenesis and drug target identification
(13). A number of animal species have been used for TB models, including mice, guinea
pigs, rabbits, and nonhuman primates. Each model has its pros and cons, including the
extent to which it represents human TB with respect to clinical signs, pathological
changes, bacterial loads in organs, disease progression, and immunological parameters
(13, 14). Among these animal species, mouse models have demonstrated predictive
value for evaluating the efficacy of drug regimens in clinical use (15). Specifically,
BALB/c and athymic nude mice have been used as immunocompetent and immune-
deficient TB models, respectively, in preclinical efficacy studies. Assuming infection with
a virulent strain of M. tuberculosis, the infectious dose, the incubation time, and the
onset and efficacy of the adaptive immune response primarily determine whether
infected mice will limit bacterial replication and contain the infection or succumb to an
overwhelming infection (16). The type of model employed can therefore have a
profound impact on the interpretation of drug or vaccine effects (15, 17). As such, an
appropriate understanding of the relationships between the infection conditions and
the development of effective adaptive immune responses is critical in applying murine
TB models appropriately in research.
Despite the important role of the adaptive immune response in suppressing bac-
terial replication and facilitating the action of TB drugs, quantitation of adaptive
immune effects has been challenging due to the complexity of the immune response.
Various mathematical models have been developed to describe immunological re-
sponses to pathogens at the molecular, cellular, and tissue levels (18–25). We recently
developed a mathematical model describing bacterial growth, an adaptive immune
effect, and drug treatment effects, established a precedent for using a baseline model
ofM. tuberculosis infection in mice for determining pharmacokinetics/pharmacodynam-
ics (PK/PD) relationships for TB drugs, and translated the findings into human trial
simulations to predict treatment outcomes (26). However, the baseline model devel-
oped in that work described the adaptive immune effect as a function of incubation
time relying on the difference in lung CFU counts observed between immunocompe-
tent BALB/c mice and immune-deficient athymic nude mice, which did not account for
the limited adaptive immune response that occurs in athymic nude mice due to T-cell
maturation outside the thymus (27). In addition, this approach did not explicitly
account for the influence of bacterial number on the development of the adaptive
immune effect in BALB/c mice, especially when CFU counts in different mice happen to
be the same, although the size of the infectious dose and the incubation time are
different. Because diverse mouse models, including acute, subacute, and chronic
infection models, are used in TB drug development to understand antibacterial activity
under time-varying immunological conditions against bacterial populations of differing
sizes and growth rates, both during and after treatment, wider application of a baseline
infection model requires consideration of these factors.
In the current work, we integrate the impact of both bacterial burden over time
without treatment and infection incubation time and develop a general mechanism-
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based baseline model of the bacterial infection, reinfection, and relapse profile and
underlying adaptive immune system response. To that end, we pool data from 86
experiments in BALB/c and nude mice of various infection models (acute, subacute, and
chronic) with various incubation periods and infection loads. Our objective is to
demonstrate that this baseline model can be applied for numerous scenarios of
preclinical studies to quantitatively describe and understand the involvement of adap-
tive immune responses and the corresponding effects of various treatment interven-
tions.
RESULTS
Differential bacterial growth profile in BALB/c mice and athymic nude mice. In
total, 74 and 12 studies evaluating various drugs, drug combinations, and infectious
dose-response effects in the absence of treatment after aerosol infection of BALB/c and
athymic nude mice, respectively, were collected. The data from the untreated control
arm of each study were pooled for modeling the bacterial burden dynamics in the
lungs over time. A spaghetti plot shows the bacterial growth profiles in each mouse
strain (Fig. 1). As expected, the size of the infectious dose determined the peak CFU
count in BALB/c mice, and higher infectious doses (e.g., 3 log10 CFU) caused mouse
FIG 1 Raw data of bacterial growth in BALB/c mice (top) and athymic nude mice (bottom). Circles
indicate raw data observed; dashed lines indicate median values of raw data.
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death more often than did lower infectious doses after the same incubation period, e.g.,
28 days, in both mouse strains (Fig. S1).
Model describing bacterial growth dynamics in BALB/c and athymic nude mice.
The most parsimonious mechanism-based model to describe mycobacterial growth
was adopted, which contained a single bacterial compartment with first-order rate
constants for bacterial replication (Kg) and bacterial death (Kd) (28). Despite being
initiated upon the inhalation of infectious aerosol droplets, the innate immune re-
sponse has little immediate antimycobacterial effect, as mentioned previously (6). The
onset of the more effective adaptive cell-mediated immune response is delayed until 11
to 14 days after inoculation in BALB/c and other immunocompetent mice (5, 6).
Therefore, our baseline model included parameters for bacterial replication, bacterial
natural death, and bacterial growth control by the adaptive immune response in the
mouse lung (16, 28). Because the increase in bacterial number exhibited a log-linear
profile up to 2 weeks after inoculation, the change in bacterial number (B) over time
was informed by the difference of the bacterial replication rate (Kg) and the natural
death rate (Kd), with minimal contribution of the inhibitory adaptive immune effect
during the early incubation stage. Under those conditions, the initial growth dynamics
of the bacteria can be explained by equation 1. Since only the result of the net growth
rate (Kg  Kd) can be estimated, Kd in the model was fixed to a literature value
(0.41 day1) (29), and Kg was then estimated.
dB
dt
 Kg B Kd B (1)
To supplement the preexisting study data that we collected, we performed an
additional experiment that investigated the impact of the infectious dose size on
bacterial growth in BALB/c and athymic nude mice with intensive sampling time points
for CFU counts (Fig. S2). The intensive sampling in that experiment revealed an initial
lag period after inoculation in which bacterial growth was extremely slow. Therefore, a
turning point was used to differentiate the slow growth right after inoculation and the
rapid growth developing afterwards. As such, for all BALB/c studies, Kg was estimated
as two different values during the early incubation period. Based on the observed data,
day 4 postinfection was identified as the turning point at which the Kg value changed
to reflect rapid bacterial replication.
The timing of the onset of the adaptive immune effect was then added. The
observed data in BALB/c mice and estimated Kg value revealed that the bacterial
growth rate decreased slightly as the length of incubation increased from 7 days to
18 days postinfection across studies before reaching a plateau, which implied the slow
onset of an effective adaptive immune response over the first 3 weeks of incubation. In
contrast, although bacterial replication in athymic nude mice after low infectious doses
started slowing at a similar time, replication continued until the end of the incubation
period or the death of the mice. This confirms that the adaptive immune response is
significantly less effective in athymic nude mice compared to that in BALB/c mice. With
high infectious doses of more than 3 log10 CFU, BALB/c mice and athymic nude mice
both would die shortly after the early stage due to the high burden of bacteria in the
lung and the insufficient time for the immune effect to respond.
The adaptive immune effect in BALB/c mice was included in the model using data
from both early and late incubation stages. The adaptive immune effect on the
bacterial replication was previously described as a nonlinear (sigmoidal) function of
bacterial load, with maximal immune effect (KB) and bacterial load that stimulates half
of the maximal effect (B50) (28, 30–32). A Hill coefficient (B) with an initial value of 1
was added to allow for the estimation of the steepness of the sigmoidal curve. As such,
the change in bacterial number over time was made dependent on the bacterial
replication rate (Kg) using a first-order function with the adaptive immune effect using
a sigmoidal function as an inhibitory effect on bacterial growth (1  KB  BB ⁄
B50
B  BB) (equation 2) (Fig. 2).
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dB
dt
 Kg B 1 KB BBB50B BB Kd B (2)
The timing of the onset of adaptive immunity is critical to the dynamics of bacterial
infection. The delayed onset of the adaptive immune response after primary infection
allows bacteria to multiply up to a point at which protective adaptive immunity is activated
to suppress bacterial multiplication and control the infection. The size of the infectious dose
plays an important role in the ability of the infected host to control the infection, namely,
the higher the infectious dose, the sooner the bacterial number approaches a tipping point
where it exceeds the ability of the host to survive the infection even if treatment is initiated.
Lower, nonlethal infectious doses allow sufficient time for the adaptive immune
effect to constrain bacterial multiplication before reaching this tipping point.
However, the level at which the bacterial burden peaks prior to containment is
directly correlated with the size of the infectious dose, as is the subsequent plateau
at which the bacterial burden stabilizes, which may be lower than the peak if the
adaptive immune effect is strong enough (16). In our studies, it was evident that
mice receiving high infectious doses died with high (and increasing) bacterial
burdens at the later incubation stage (i.e., 3 to 5 weeks postinfection), although the
bacterial numbers in those mice on day 14 postinfection were often similar to the
bacterial numbers on day 28 postinfection in mice receiving lower infectious doses
that prevented further multiplication, which did not die (Fig. 3). Therefore, bacterial
number is not the only variable that determines the magnitude of the adaptive
immune effect in that different incubation times could result in the same CFU counts
in the lungs after different infectious doses, where the adaptive immune effect could
be significantly different. As such, a time-dependent adaptive immune effect compo-
nent (time covariate) was formulated as a sigmoidal function [KT  tT ⁄T50T  tT],
with T50 as the number of days required to reach half of the time covariate effect, KT as
the maximal magnitude of time covariate effect, and T as the steepness of the time
covariate curve versus time. The time covariate was added simultaneously with the
CFU-dependent adaptive immune effect component [KB  BB ⁄B50
B  BB], as an
inhibitory effect on bacterial growth [1  KB  BB ⁄B50
B  BB  1  KT  tT ⁄
T50T  tT] (equation 3). This reformulated baseline model better described the
bacterial burden over time in BALB/c mice compared to the previous model with the
adaptive immune effect solely dependent on bacterial number, regardless of whether
the immune effect function was implemented on the bacterial growth or death
component (change of objective function value [ΔOFV]  944.407 and 819.73,
FIG 2 Structural baseline model. A single bacterial compartment (B) with first-order rate constants for
logarithmic bacterial replication (Kg) and natural bacterial death (Kd) was used to describe the rapid
growth of bacteria during the early infection phase. The adaptive immune effect that controls bacterial
infection was described by the following sigmoidal function on both bacterial load and incubation time:
f
immune
B,t. The bacterial growth rate is decreasing as the development of the adaptive immune effect
depending on the bacterial number and time of incubation.
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respectively; degrees of freedom [df]  4; P 0.01). The inhibitory effect on bac-
terial growth was superior to the stimulatory effect on bacterial death (ΔOFV 
45.498, df 0; P 0.01).
dB
dt
 Kg B 1 KB BBB50B BB 1 KT t
T
T50
T tT Kd B (3)
It is known that immune-deficient athymic nude mice have a modest amount of T-cell
maturation outside the thymus, so they do not have a completely absent adaptive immune
response (27). As a result, a similar baseline model was built for athymic nude mice, in
which change in bacterial number over time was dependent on bacterial replication rate
and natural death rate in a first-order function, and the adaptive immune effect was a
sigmoidal function of bacterial load and time individually added on bacterial growth rate
(equation 3). This reformulated baseline model provided a better fit to the data than the
preceding model without a time covariate, even for the minimal adaptive immune effect in
athymic nude mice (ΔOFV  128.205; df 3; P 0.01). The goodness of fit plots show
that the structural and residual error models are able to describe the data of BALB/c and
athymic nude mice well (Fig. S3A and B, respectively).
Visual predictive check (VPC) inspections indicated that for both mouse models, the
median and 95% confidence interval (CI) of the observed data were consistently within
the 90% CI of the median and the 95% prediction interval of the simulated bacterial
number (Fig. 4).
Overall, the adaptive immune effect on bacterial replication is dependent on the
bacterial number and incubation time. The maximal level of the adaptive immune
effect stimulated in BALB/c mice is much higher than that in athymic nude mice (Fig.
5). Since there is minimal adaptive immune response in athymic nude mice, the
estimate of maximal adaptive immune effect that comes from the bacterial number (KB)
for athymic nude mice model is lower than that for BALB/c mice (9.01% versus 20.3%)
and requires a lower bacterial number (B50) to reach half of that level (4.65 versus 7.86
log10 CFU) (Table 1 and Fig. 5, top left). The maximal adaptive immune effect that
comes from the incubation time (KT) for athymic nude mice model is also lower than
that for BALB/c mice (46.2% versus 70.2%). Interestingly, the time to reach half of the
maximal time covariate was slightly longer in athymic nude mice than in BALB/c mice
(19.2 versus 17.4 days) (Table 1 and Fig. 5, bottom left). In both mouse models, the
time-dependent effect component dominates the development of the adaptive im-
mune effect with a higher KT over KB (Table 1).
FIG 3 Impact of incubation time on bacterial infection in BALB/c mice. Although inoculum size differed
by only half a log, bacterial infection showed nonparallel profiles and different infection outcomes in
mice. The CFU count for the dead mice is an estimate based on experience.
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Bacterial relapse and preimmunity. We previously observed that the bacterial
burden in the lungs of BALB/c mice relapsing after combination chemotherapy in-
creases with time after treatment completion but peaks around 4 log10 CFU, a level
significantly lower than that observed with primary infection. Therefore, we presumed
that the adaptive immune response reacts differently (and more effectively) during the
relapse due to the immunological memory from the primary infection. It is known that,
in the first 2 to 3 weeks after primary infection, the bacteria multiply in the lung under
the negligible antibacterial effect of the predominantly innate immune response and
disseminate from the lung via the lymphatic drainage (5, 6, 16). Once the bacteria arrive
in the draining lymph nodes, T cells are slowly activated within the draining lymph
node to initiate acquired cell-mediated immunity, and antigen-specific memory is
triggered at the same time. Then, the acquired cellular immunity is initiated (16, 33). In
order to explore the dynamics of the adaptive immune effect during and after com-
bination chemotherapy, the combined drug effect (EFF) of a first-line regimen of
rifampin-isoniazid-pyrazinamide (RHZ) was first estimated using historical data with the
assumption that the adaptive immune effect remains at its peak, which is reached close
to the time when drug treatment started (day 32 postinfection), until the end of
treatment (day 102 postinfection). First, in simulations, our baseline model was able to
FIG 4 Visual predictive checks for baseline model of BALB/c mice (top) and athymic nude mice (bottom)
(N 200). The final baseline model for both BALB/c and athymic nude mice is able to describe the
observed data.
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predict the CFU counts before treatment started. For RHZ treatment beginning 32 days
postinfection, the drug effect (EFF) was assumed to be constant during each period
between sampling time points and estimated as either a percent inhibition of bacterial
growth or a percent acceleration of bacterial death, which turned out to have the same
OFV values (equations 4 and 5). To simplify the interpretation, the model with the drug
effect (EFF) as an inhibitory effect on bacterial growth was used. The effect estimate of
FIG 5 Model behavior. (A) Relationship between bacterial number and CFU-dependent adaptive immune effect
(top left) and relationship between incubation days and time-dependent adaptive immune effect (bottom left) in
BALB/c mice and athymic nude mice. Shaded area indicates the uncertainty of parameter estimates. (B) Relation-
ship between bacterial number, incubation days, and total adaptive immune effect in BALB/c mice (top right) and
athymic nude mice (bottom right). Black line shows a typical profile observed; gray shaded area is the simulated
range of bacterial number throughout incubation using the inoculums of the observed data.
TABLE 1 Parameter estimates of baseline model for BALB/c and athymic nude mice
Parameter (unit) Description
Values (relative SD [%]) for:
BALB/c mice Athymic nude mice
Kg (day1) Bacterial growth rate 1.22 (3) 1.14 (5)
Kd (day1) Bacterial death rate 0.41 (fixed) 0.41 (fixed)
KB (%) Maximal inhibitory CFU-dependent adaptive immune effect 20.3 (19) 9.01 (15)
B50 (log10 CFU) CFU counts to reach half of KB 7.86 (3) 4.65 (13)
B Steepness of the CFU-dependent adaptive immune effect curve 3.11 (10)
KT (%) Maximal inhibitory time-dependent adaptive immune effect 70.2 (1) 46.2 (11)
T Steepness of the time-dependent adaptive immune effect curve 5 (5) 4.78 (28)
T50 (days) Time to reach half of maximal time covariate 17.4 (4) 19.2 (15)
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RHZ was 71.9% inhibition for days 0 to 14 of treatment, 52.5% inhibition for days 14 to
28 of treatment, and 33.4% inhibition for days 28 to 70 of treatment using our model.
dB
dt
 Kg B 1 KB BBB50B BB 1 KT t
T
T50
T tT (1 EFF) Kd B (4)
dB
dt
 Kg B 1 KB BBB50B BB 1 KT t
T
T50
T tT Kd B (1 EFF) (5)
Having observed that bacteria started regrowing after removal of the antibacterial
effect of the drug treatment, we presumed that immune recall responses were likely
initiated following a similar but much faster process due to the memory of antigen-
specific T cells (16, 33). It is even possible that the adaptive immune effect never
disappeared entirely, since there were always live bacteria and bacterial antigens in the
lung. As such, we extended our model to describe bacterial regrowth during relapse by
adopting an accelerated adaptive immune response. We first reestimated T50 in the
time covariate of the model by resetting the time at day 102 postinfection when drug
treatment was stopped, since bacterial number had decreased significantly during the
course of treatment. This turned out to be 6.59 days, which is consistent with the
assumptions that the recall immune response is faster than the primary immune
response or that the adaptive immune effect stayed at a relatively high level during
treatment (16, 33), which results in much slower bacterial growth after treatment stops.
With the reestimated T50 value indicating faster onset of immune effect, our baseline
model was able to predict not only bacterial growth during the primary infection but
also slower growth during relapse (Fig. 6).
Significant impact of adaptive immune response on assessing drug effect. We
previously observed very different effects of pyrazinamide (PZA) in mouse efficacy
studies, depending on the duration of the incubation period and the immune compe-
tence of the mouse strain (11, 14), leading us to consider that the PZA effect is
dependent on the adaptive immune response (15, 34). Modeling these prior data using
our baseline model, we observed that during treatment with PZA alone, the bacterial
number followed very different time courses in the subacute model than those in the
chronic model, despite starting at a similar level in both models (6.5 to 7.3 log10 CFU)
(Fig. 7, top). In the subacute model, bacterial number initially increased by around
one-half log10 CFU for the first 14 days of treatment (to 7.7 log10 CFU), and then
decreased by around 1.5 log10 CFU and 3 log10 CFU (to6 and4.7 log10 CFU) on days
28 and 56, respectively, of treatment. In contrast, bacterial number decreased imme-
diately with treatment in the chronic infection model, i.e., by 0.5 log10 CFU (to6 log10
CFU) after 7 days of the same treatment in the chronic model, and by another 0.5
FIG 6 Prediction of bacterial relapse in BALB/c mice after RHZ treatment. Using a shorter T50, our baseline
model is able to predict the bacterial number during the relapse.
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log10 CFU and 1 log10 CFU (to 5.5 log10 CFU and 5log10 CFU) on days 14 and 28,
respectively, of treatment. Similarly, we estimated the drug effect of PZA as a percent
inhibitory effect on bacterial growth on top of the adaptive immune effect for each
period between sampling points, using our model with the assumption that the
adaptive immune effect followed the sigmoidal function of bacterial number and time
until it reached the highest level during the incubation period, which is around day 14
after treatment started for the subacute model and day 0 for the chronic model. It was
found that the effect estimate of PZA was 23.9% inhibition for days 0 to 14, 62.0%
inhibition for days 14 to 28, and 14.6% inhibition for days 28 to 56 of treatment (days
14–28, 28 to 42, and 42 to 70 postinfection, respectively) in the subacute infection
model, compared to 131% inhibition for days 0 to 7 (an inhibitory effect greater than
100% implies that PZA kills the bacteria immediately when it is on board), 39.2%
inhibition for days 7 to 14, and 15.1% inhibition for days 14 to 28 of treatment (days 35
to 42, 42 to 49, and 49 to 63 postinfection, respectively) in the chronic infection model
(Fig. 7, bottom). This shows that drug effect of PZA differs at different stages during
FIG 7 Differential treatment response of PZA monotherapy (top) and time-varying drug effect of PZA
(bottom) in chronic (35 days) and subacute study (14 days) in BALB/c mice. Circle, raw data observed; solid
line, median value of raw data; – - – -, predicted effect. Drug effect at a similar time period postinfection
is similar between subacute and chronic infection study, although the incubation period without drug
treatment is different.
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incubation and is likely significantly influenced by the development of the adaptive
immune response such that, at a similar infection time, the PZA effect is comparable in
the subacute and chronic models (Fig. 7, bottom).
Protective immune effect in BALB/c mice as TB vaccine model. The baseline
model that describes the bacterial growth with primary immune response and recall
immune response was then tested using data from a paucibacillary mouse TB model
following prior immunization with M. bovis BCG by the aerosol or intravenous route
(35). Six weeks after immunization, mice were aerosol challenged with virulent Myco-
bacterium tuberculosis H37Rv (Fig. 8). Although the mice immunized via different routes
started with almost identical counts of BCG in the lung on days 1 and 14 postimmu-
FIG 8 Bacterial growth and adaptive immune effect profiles in the immunization and challenge study.
Circle, median value of raw data observed; solid line, profiles of the median value of raw data. (Top) M.
bovis BCG growth profiles via aerosol or intravenous infection in the immunization study. (Middle) M.
tuberculosis H37Rv growth profiles in mice in the challenge study immunized via aerosol or intravenous
infection of M. bovis BCG and in naive mice. (Bottom) Simulated immune effect described by the baseline
model with different T50 values for the infection of M. tuberculosis H37Rv in mice in the challenge study.
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nization, they ended up with significantly different CFU counts at the peak on day 28
and later reached a similar plateau on days 63 and 84 (Fig. 8, top). The growth profile
of M. tuberculosis after challenge differed depending on whether the mice were
immunized and on the route of immunization (Fig. 8, middle). Compared to nonim-
munized mice, immunized mice had much lower CFU counts after challenge, with
aerosol-immunized mice having the lowest counts. This is the inverse of the growth
profiles of M. bovis BCG in the immunization period, where aerosol-immunized mice
contained higher CFU counts, which resulted in a greater adaptive immune response
according to our model. The immune effect acquired in the immunized and nonim-
munized mice via aerosol challenge of M. tuberculosis H37Rv was reestimated by
assuming that the dynamics of the protective cell-mediated memory response to
aerosol challenge is accelerated like that observed after the end of drug treatment in
the relapse study. Similarly, we reestimated T50 in the time covariate of the model,
which turned out to be 13.1 days for mice immunized via the intravenous route and
9.54 days for mice immunized via the aerosol route, compared to 19.3 days for nonim-
munized mice (Fig. 8, bottom). Reestimation of other parameters, including KT, KB, B50,
KT, and T50, or KB and B50, did not result in altered estimates and/or better model fitting.
This result also supports the assumption that the protective memory response acts
faster in the BCG-primed mice than in the naive mice and when immunization occurs
via the aerosol route compared to the intravenous route, consistent with the ability of
antigen-specific memory T cells to get to the lungs quickly upon infection and/or to
more rapidly populate the lung as a measure of the recall adaptive immune response.
DISCUSSION
The differences in bacterial growth profiles between BALB/c and athymic nude mice
observed in the data that we collected are intuitive (Fig. 1 and Fig. S1 and S2). The
interplay of infectious dose, the timing of the onset and the magnitude of the adaptive
immune effect, and the incubation time is critical regarding the bacterial infection
dynamics and the survival of mice. Within the same incubation time, BALB/c mice
receiving low infectious doses were less likely to die than those receiving high infec-
tious doses and athymic nude mice receiving low or high inoculums. All of these
factors, including bacterial number, incubation time, and maximal CFU- and time-
dependent adaptive immune effects, have been included in the model to describe the
adaptive immune response during M. tuberculosis infection of mice (equation 3).
Our model shows, for the first time, that the adaptive immune effect in mouse TB
models is dependent on both bacterial number and duration of incubation (Fig. 5). The
heat map plot shows the 3-dimensional relationship between bacterial number, incu-
bation time, and total adaptive immune effect for BALB/c and athymic nude mice (Fig.
5, top right and bottom right). The time to the onset of the adaptive immune effect is
around 7 to 9 days after infection for BALB/c mice (transition from blue to gray shaded
ribbon area) and it takes 25 to 28 days to reach the maximal level (dark red shaded
ribbon area), which is consistent with prior observations from animal studies (6). The
levels of infectious dose do not affect the magnitude of the adaptive immune effect
significantly, since the color change over the incubation time is almost the same across
the infectious dose range in the shaded ribbon area. Based on our model, a 10-fold
infectious dose would only increase the maximal immune effect by no more than 5%
inhibition on the growth on day 28 for the four arms receiving different infectious doses
in BALB/c mice (Fig. 5, top right, and Fig. S2). This implies that the arrival of the plateau
of the adaptive immune effect can only be accelerated by 1 or 2 days (16). For athymic
nude mice with a modest amount of T-cell maturation outside the thymus, the immune
effect starts around the same time as in BALB/c mice, but the magnitude of both the
maximal CFU- and time-dependent immune effects is much lower than in BALB/c mice,
as expected (Fig. 5, bottom right, and Table 1). Interestingly, the bacterial number at
which the half-maximal CFU-dependent immune effect appears is much lower for nude
mice, with a slightly longer time to reach the half-maximal time covariate than BALB/c
mice (Fig. 5, top left and bottom left, and Table 1).
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Precise quantification of bacterial growth dynamics and immune response was
necessary to accurately describe the efficacy of pyrazinamide in subacute and chronic
mouse models. PZA is a key sterilizing drug in the first-line TB regimen. Its antibacterial
activity is highly dependent on the pH of the environment in vitro and in vivo, with MICs
decreasing by an order of magnitude with each unit change in pH values (37). PZA
exerts strong initial bactericidal activity in the chronic BALB/c mouse infection model,
since the infecting bacilli are virtually all intracellular, residing in the acidified environ-
ment in the phagosomes of activated macrophages, where the pH can be as low as 4.5
(34, 37). On the other hand, the bactericidal effect of PZA monotherapy in the subacute
BALB/c infection model is delayed. The slight increase in CFU counts during the first 2
weeks of treatment in this model, before the peak of the adaptive immune response,
is presumably due to the lack of a suitably acidic environment in naive macrophages
for the active metabolite of PZA, pyrazinoic acid (POA), to become protonated and to
permeate through the membrane into the bacilli (38). Since the adaptive immune
response takes around 17 days to reach half of the maximal time covariate, which
accounts for 70% inhibition in our model, it implies that a longer incubation time is
required before the phagosomes containing the bacilli mature and acidify following
activation by T cells (5, 6). This explains why, after 14 days of treatment in the subacute
study (to reach day 28 postinfection), PZA started exerting bactericidal activity similar
to that observed in the chronic infection model in which treatment was initiated
35 days postinfection (Fig. 7). In our baseline model, it was found that the adaptive
immune effect reaches its maximum level after 25 to 28 days of incubation without any
treatment in BALB/c mice (Fig. 5, top right, dark red shaded ribbon area). Therefore, a
precise description of the development of adaptive immune effects in various mouse
models plays an important role in understanding the dynamics of PZA activity (11, 15)
and should be similarly useful for understanding the activity of other drugs that may
depend on a component of the immune response for optimal activity.
The relatively low CFU counts that bacteria reached in relapsing mice implied that
the adaptive immune effect stimulated by primary infection might either remain high
or gradually decline during treatment, as the bacterial number decreases to a much
lower level before the regrowth (Fig. 6). We considered that the bacteria that regrow
arise from persistent or resistant bacteria with mutations selected by the chemother-
apy, which might grow more slowly due to a mutation-induced loss of fitness. However,
experience tells us that the relapsing bacteria are fully drug susceptible and equally fit
as the wild type, at least in most cases, so it is challenging to accept that the bacteria
causing relapse are somehow less fit. Instead, an immunizing effect of the primary
infection that limits the regrowth of bacteria in the lung during relapse fits better here
since it is similar to the scenario of vaccination, in which adaptive immunity against the
infection has been acquired. In fact, the vaccination/challenge study supported this
explanation, in that a similar plateau around 4 log10 CFU was observed in the mice
which were immunized with a BCG vaccine strain via the aerosol route and then
infected with M. tuberculosis via aerosol 6 weeks later as a challenge (Fig. 8) (35). In
contrast, in the mice without prior immunization with BCG, bacterial growth followed
the typical profile up to 6 log10 CFU or more (Fig. 1). In the relapse study, although it
is not entirely clear whether the adaptive immune effect decreased during the treat-
ment period or remained at the same high level as that when treatment started, a
shorter T50 indicating faster immune response onset (almost instantaneous) was used
to describe the lower plateau of CFU counts during relapse. This suggests that either
the recall adaptive immunity was reactivated to immediately reach a high level or that
it never faded away. While the fact that the bacterial counts increased at all strongly
suggests that the immune effect must have decreased to some degree during treat-
ment, more intensive sampling of CFU counts during the early growth period of
reinfection or relapse is needed to further investigate this detail. In the case of
challenge infection after immunization, the ability of memory T cells either to populate
the lung or to get to the lungs quickly upon infection determines the recall protective
adaptive immune response (16). It is also interesting to see that the reestimated T50
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may be inversely related to the plateau level of M. bovis BCG in the immunization
period, which implies the quantity of the memory T cells could determine the recall
response (Fig. 8). Therefore, our baseline model can also be used for characterizing the
dose-response relationship of TB vaccines. Besides the application of our model in
reinfection/relapse, some considerations about modeling exposure-response relation-
ships of TB drugs or regimens have been explored, such as how to formulate the
adaptive immune effect when drug is on board. The adaptive immune effect may never
go away or could be rapidly recalled, even if bacterial numbers drop significantly.
According to our model, the time-dependent component contributes much more than
the CFU-dependent component to the magnitude of the immune effect. Therefore, the
drop in bacterial number may not make as significant an impact on the level of immune
effect. This assumption regarding the change of adaptive immune effect during treat-
ment period will be further investigated experimentally and mathematically.
In conclusion, we present here a mechanism-based baseline model ofM. tuberculosis
infection in BALB/c and athymic nude mice, which mathematically describes the
dynamics of bacterial growth and the adaptive immune effect. We also expanded this
model to describe the bacterial profile during treatment with PZA, during relapse after
inadequate treatment, and during challenge infection after vaccination. As pointed out,
the adaptive immune response has a deterministic role in the evolution of infecting
bacterial populations throughout the period of infection, including assisting the action
of PZA, as well as mediating protective effects via prior infection and vaccination. Our
baseline model is therefore a useful tool to quantify the adaptive immune effect elicited
by pathogenic mycobacteria or preventive vaccines. The quantitation of the adaptive
immune effect will be important to understand the efficacy of TB drugs, regimens, and
vaccines in preclinical studies and provide better prediction of clinical trial outcomes for
new treatment against TB disease.
MATERIALS AND METHODS
Experimental data from studies evaluating growth in untreated mice. In total, data from 74 and
12 published and unpublished mouse efficacy studies evaluating TB drugs or regimens in BALB/c and
athymic nude mice, respectively, were collected. Mice in each experiment were block randomized to
treatment assignment after aerosol infection of M. tuberculosis H37Rv. The infectious dose ranged from
0.5 to 4.8 log10 CFU, depending on the experiment. Lung CFU counts were collected at prescribed time
points to assess the growth of M. tuberculosis.
An additional study was performed to supplement the historical data by evaluating the impact of
infectious dose size on bacterial growth in BALB/c and athymic nude mice. The infectious doses
evaluated included below 2 log10 CFU, 2 to 3 log10 CFU, 3 to 4 log10 CFU, and more than 4 log10 CFU.
Mice of each strain were block randomized to different infectious doses of M. tuberculosis H37Rv
administered via aerosol. Three mice per strain were sacrificed and lung CFU counts were collected at
days 1, 2, 4, 7, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 35, 42, 46, 49, and 50 postinfection to assess the growth
of M. tuberculosis.
Experimental data from a study evaluating relapse after combination chemotherapy. Mice
were block randomized to treatment groups after low-dose aerosol infection of M. tuberculosis H37Rv
and incubated for 32 days before treatment with a combination of rifampin (10 mg/kg), isoniazid
(10 mg/kg), and PZA (150 mg/kg) (RHZ) dosed daily by gavage, 5 days per week for 10 weeks. After the
treatment stopped, the mice were kept for another 6 weeks to capture the regrowth. Lung CFU counts
were collected at prescribed time points during and after treatment to assess the growth of M.
tuberculosis.
Experimental data from studies evaluating response to PZA treatment. For the studies that
evaluated efficacy of PZA monotherapy, mice in each experiment were block randomized to treatment
groups after low-dose aerosol infection of M. tuberculosis H37Rv and incubated for 14 days (subacute
model) or 35 days (chronic model) before treatment with PZA. PZA (150 mg/kg) was dosed daily by
gavage, 5 days per week, for 8 weeks (subacute model) and 4 weeks (chronic model). Lung CFU counts
were collected at prescribed time points to assess the growth of M. tuberculosis.
Experimental data from a study evaluating the effect of BCG immunization on M. tuberculosis
challenge infection. Mice were block randomized to receive either aerosol immunization or intravenous
immunization with M. bovis BCG or to a control arm without immunization, as previously described (35).
Six weeks after immunization, all mice were challenged by the aerosol route with M. tuberculosis H37Rv.
CFU counts were collected at day 1, week 2, week 4, and week 6 postimmunization to assess the growth
of BCG and at day 1, week 3, and week 6 postchallenge to assess the growth of BCG and M. tuberculosis
after challenge.
Model development. Model development and data analysis was conducted using nonlinear mixed-
effects modeling (NONMEM 7 software; ICON Development Solutions, San Antonio, TX) (39). Data
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analyses, diagnostics, and visualization were performed using R packages (R-3.1.1, Development Core
Team) (40). The first-order conditional estimation with interaction method (FOCEI) was used.
Bacterial growth was described by a baseline model, which accounts for bacterial replication,
bacterial natural death, and inhibition imposed by the adaptive immune response. The adaptive immune
effect was described by a sigmoidal function depending on the scenarios described. The recall adaptive
immune effect in the relapse study and the immunization/challenge study was formulated the same as
that in the baseline model, with one or two parameters reestimated. Model optimization was guided by
the likelihood ratio test (LRT) for the nested model, diagnostic plots, and internal model validation
techniques, including visual predictive checks. When additional parameters were included, a decrease of
3.84 points (P 0.05 for 1 degree of freedom [df]) was considered statistically different.
The combined effect of RHZ treatment in the relapse study and the effects of PZA treatment in the
monotherapy studies were estimated as constant values during each period between sampling time
points. Observed drug effects were estimated as percent changes on top of the adaptive immune effect
on the bacterial growth rate in the baseline model.
Visual diagnostic plots at all major steps of model development were used to characterize goodness
of fit of observations to predictions for both BALB/c and athymic nude mice. VPCs were performed to
evaluate the simulation properties of the final baseline models, using 200 simulations based on final
baseline parameter values (including the inter- and intraindividual variability) for both BALB/c and
athymic nude mouse models.
Data availability. The data used in this research were generated in-house. The data in this work are
mainly the CFU counts over incubation time in a TB mouse model with or without any chemotherapy
treatment. Data are available upon request.
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